{"id":53270,"date":"2026-01-08T00:43:48","date_gmt":"2026-01-07T16:43:48","guid":{"rendered":"https:\/\/flcube.com\/?p=53270"},"modified":"2026-01-08T00:43:49","modified_gmt":"2026-01-07T16:43:49","slug":"mabwell-partners-with-sentonix-on-neurodegenerative-disease-drug-discovery-alliance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53270","title":{"rendered":"Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Mabwell (Shanghai) Bioscience Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688062:SHA\">SHA: 688062<\/a>) announced a <strong>global strategic cooperation agreement<\/strong> with <strong>Sentonix, Inc.<\/strong>, a Massachusetts\u2011based biotech specializing in <strong>precision neurodegenerative disease therapies<\/strong>, to jointly discover and develop <strong>next\u2011generation drugs for Parkinson\u2019s disease, Alzheimer\u2019s disease, and other neurodegenerative disorders<\/strong> through co\u2011development, NewCo formation, and regional licensing models.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-overview\">Partnership Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Mabwell (688062.SH), Sentonix, Inc.<\/td><\/tr><tr><td><strong>Focus Areas<\/strong><\/td><td>Parkinson\u2019s, Alzheimer\u2019s, neurodegenerative diseases<\/td><\/tr><tr><td><strong>Collaboration Models<\/strong><\/td><td>Co\u2011development, NewCo formation, regional licensing<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>Global<\/td><\/tr><tr><td><strong>Strategic Goal<\/strong><\/td><td>Seamless integration from early discovery to clinical translation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partner-profiles\">Partner Profiles<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Description<\/th><th>Market Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Mabwell (Shanghai)<\/strong><\/td><td>Listed biotech platform company with biologics and ADC capabilities<\/td><td>Strong clinical translation expertise in China<\/td><\/tr><tr><td><strong>Sentonix, Inc.<\/strong><\/td><td>Private Massachusetts\u2011based biotech founded by imaging scientists<\/td><td>Pioneering biomarker\u2011guided neuroscience drug discovery<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Complementary Strengths<\/strong>: Sentonix\u2019s <strong>biomarker\u2011guided platform<\/strong> (using imaging and molecular markers for patient selection) combines with Mabwell\u2019s <strong>biologics R&amp;D and clinical translation capabilities<\/strong> in China.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Market Need<\/strong>: Addresses <strong>critical unmet need<\/strong> in neurodegenerative diseases where <strong>clinical trial failure rates exceed 90%<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Platform Validation<\/strong>: Sentonix\u2019s approach has demonstrated success in <strong>precision patient stratification<\/strong>, potentially increasing success rates for Mabwell\u2019s pipeline.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>China Neurodegenerative Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Parkinson\u2019s Disease<\/strong>: <strong>3\u202fmillion<\/strong> patients, <strong>\u00a512\u202fbillion<\/strong> market (2025), growing at <strong>16% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Alzheimer\u2019s Disease<\/strong>: <strong>10\u202fmillion<\/strong> patients, <strong>\u00a528\u202fbillion<\/strong> market (2025), growing at <strong>18% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Total Addressable Market<\/strong>: <strong>\u00a550\u202fbillion<\/strong> (US$7\u202fbillion) across neurodegenerative diseases by 2030<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Global Market<\/strong>: <strong>$120\u202fbillion<\/strong> (2025), with <strong>significant unmet need<\/strong> for disease\u2011modifying therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Platform\/Asset<\/th><th>Focus<\/th><th>Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>Biogen<\/strong><\/td><td>Aduhelm, Leqembi (anti\u2011A\u03b2)<\/td><td>Alzheimer\u2019s<\/td><td>Marketed<\/td><\/tr><tr><td><strong>Roche\/Genentech<\/strong><\/td><td>gantenerumab, troriluzole<\/td><td>Alzheimer\u2019s, PD<\/td><td>Phase\u202fIII<\/td><\/tr><tr><td><strong>Eli Lilly<\/strong><\/td><td>donanemab (anti\u2011A\u03b2)<\/td><td>Alzheimer\u2019s<\/td><td>Marketed<\/td><\/tr><tr><td><strong>Insilico Medicine<\/strong><\/td><td>AI drug discovery<\/td><td>Neurodegeneration<\/td><td>Discovery<\/td><\/tr><tr><td><strong>XtalPi<\/strong><\/td><td>AI + robotics<\/td><td>Rare diseases<\/td><td>Discovery<\/td><\/tr><tr><td><strong>Mabwell + Sentonix<\/strong><\/td><td>Biomarker\u2011guided + biologics<\/td><td>PD, Alzheimer\u2019s<\/td><td><strong>Strategic alliance<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Differentiation<\/strong>: The alliance is <strong>first to combine biomarker\u2011guided discovery with integrated biologics platform<\/strong> for neurodegeneration.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Deal Structure<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NewCo Formation<\/strong>: Potential <strong>joint venture<\/strong> with <strong>50\/50 equity split<\/strong> for lead assets<\/li>\n\n\n\n<li><strong>Regional Licensing<\/strong>: Mabwell gains <strong>Greater China rights<\/strong>; Sentonix retains <strong>ex\u2011China rights<\/strong><\/li>\n\n\n\n<li><strong>Milestone Payments<\/strong>: Estimated <strong>USD\u202f50\u2011100\u202fmillion<\/strong> in near\u2011term milestones tied to candidate nomination<\/li>\n\n\n\n<li><strong>Total Deal Value<\/strong>: Could reach <strong>USD\u202f200\u2011500\u202fmillion<\/strong> across multiple programs<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Platform Monetization<\/strong>: Sentonix\u2019s technology could generate <strong>additional licensing revenue<\/strong> from third\u2011party partnerships.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-integration\">Technology Integration<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sentonix Platform<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI\u2011driven imaging biomarkers<\/strong> for patient selection<\/li>\n\n\n\n<li><strong>Molecular diagnostics<\/strong> for target engagement<\/li>\n\n\n\n<li><strong>Clinical trial optimization<\/strong> reducing Phase\u202fIII risk<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mabwell Capabilities<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biologics discovery<\/strong> (antibodies, ADCs, bispecifics)<\/li>\n\n\n\n<li><strong>Clinical translation<\/strong> in China with <strong>regulatory expertise<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing scale<\/strong> for late\u2011stage development<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding partnership milestones, NewCo formation, clinical translation timelines, and revenue projections. Actual results may differ materially due to R&amp;D challenges, regulatory hurdles, and competitive dynamics in neurodegenerative drug development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced a global strategic cooperation agreement with Sentonix,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[118,4536,1129],"class_list":["post-53270","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-mabwell-bioscience","tag-sentonix","tag-sha-688062"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced a global strategic cooperation agreement with Sentonix, Inc., a Massachusetts\u2011based biotech specializing in precision neurodegenerative disease therapies, to jointly discover and develop next\u2011generation drugs for Parkinson\u2019s disease, Alzheimer\u2019s disease, and other neurodegenerative disorders through co\u2011development, NewCo formation, and regional licensing models.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53270\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance\" \/>\n<meta property=\"og:description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced a global strategic cooperation agreement with Sentonix, Inc., a Massachusetts\u2011based biotech specializing in precision neurodegenerative disease therapies, to jointly discover and develop next\u2011generation drugs for Parkinson\u2019s disease, Alzheimer\u2019s disease, and other neurodegenerative disorders through co\u2011development, NewCo formation, and regional licensing models.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53270\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T16:43:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-07T16:43:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53270#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53270\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance\",\"datePublished\":\"2026-01-07T16:43:48+00:00\",\"dateModified\":\"2026-01-07T16:43:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53270\"},\"wordCount\":474,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Mabwell Bioscience\",\"Sentonix\",\"SHA: 688062\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53270#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53270\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53270\",\"name\":\"Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-07T16:43:48+00:00\",\"dateModified\":\"2026-01-07T16:43:49+00:00\",\"description\":\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced a global strategic cooperation agreement with Sentonix, Inc., a Massachusetts\u2011based biotech specializing in precision neurodegenerative disease therapies, to jointly discover and develop next\u2011generation drugs for Parkinson\u2019s disease, Alzheimer\u2019s disease, and other neurodegenerative disorders through co\u2011development, NewCo formation, and regional licensing models.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53270#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53270\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53270#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance - Insight, China&#039;s Pharmaceutical Industry","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced a global strategic cooperation agreement with Sentonix, Inc., a Massachusetts\u2011based biotech specializing in precision neurodegenerative disease therapies, to jointly discover and develop next\u2011generation drugs for Parkinson\u2019s disease, Alzheimer\u2019s disease, and other neurodegenerative disorders through co\u2011development, NewCo formation, and regional licensing models.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53270","og_locale":"en_US","og_type":"article","og_title":"Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance","og_description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced a global strategic cooperation agreement with Sentonix, Inc., a Massachusetts\u2011based biotech specializing in precision neurodegenerative disease therapies, to jointly discover and develop next\u2011generation drugs for Parkinson\u2019s disease, Alzheimer\u2019s disease, and other neurodegenerative disorders through co\u2011development, NewCo formation, and regional licensing models.","og_url":"https:\/\/flcube.com\/?p=53270","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-07T16:43:48+00:00","article_modified_time":"2026-01-07T16:43:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53270#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53270"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance","datePublished":"2026-01-07T16:43:48+00:00","dateModified":"2026-01-07T16:43:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53270"},"wordCount":474,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Mabwell Bioscience","Sentonix","SHA: 688062"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53270#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53270","url":"https:\/\/flcube.com\/?p=53270","name":"Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-07T16:43:48+00:00","dateModified":"2026-01-07T16:43:49+00:00","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced a global strategic cooperation agreement with Sentonix, Inc., a Massachusetts\u2011based biotech specializing in precision neurodegenerative disease therapies, to jointly discover and develop next\u2011generation drugs for Parkinson\u2019s disease, Alzheimer\u2019s disease, and other neurodegenerative disorders through co\u2011development, NewCo formation, and regional licensing models.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53270#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53270"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53270#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53270"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53270\/revisions"}],"predecessor-version":[{"id":53274,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53270\/revisions\/53274"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}